Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | CARM1 | Q86X55 | 1/20 | 0.37 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.37 |
| ▸ | PRMT8 | Q9NR22 | 1/20 | 0.37 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.36 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.34 |
| ▸ | HTR1A | P08908 | 1/20 | 0.34 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.34 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.34 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.34 |
| ▸ | HTR7 | P34969 | 1/20 | 0.33 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.33 |
| ▸ | CACNA1I | Q9P0X4 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12025008 | 0.97 | CARM1 (0.39) | POLBCARM1PRMT6PRMT8HRH3 | |
| SCHEMBL179355 | 0.92 | CARM1 (0.44) | POLBCARM1PRMT6PRMT8HRH3 | |
| SCHEMBL19543020 | 0.92 | ALOX15 (0.38) | KCNH2ALOX15CACNA1ISIGMAR1 | |
| SCHEMBL20125805 | 0.92 | — | — | |
| SCHEMBL13246592 | 0.92 | ALOX15 (0.38) | KCNH2ALOX15CACNA1ISIGMAR1 | |
| SCHEMBL12563635 | 0.92 | ALOX15 (0.38) | KCNH2ALOX15CACNA1ISIGMAR1 | |
| SCHEMBL19543665 | 0.92 | ALOX15 (0.38) | KCNH2ALOX15CACNA1ISIGMAR1 | |
| SCHEMBL25096036 | 0.91 | CHKA (0.43) | POLBPRMT6KDM4ESIGMAR1 | |
| SCHEMBL10032106 | 0.90 | HRH3 (0.48) | POLBCARM1PRMT6PRMT8HRH3 | |
| SCHEMBL24277911 | 0.90 | HRH3 (0.48) | POLBCARM1PRMT6PRMT8HRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12036209-B2 | Compounds and methods for the targeted degradation of Interleukin-1 receptor-associated kinase 4 polypeptides | ARVINAS OPERATIONS, INC. (US) | 2024-07-16 | — | — | US | disclosed |
| WO-2024006402-A1 | SELECTIVE HISTONE DEACETYLASE 3 (HDAC3) DEGRADERS AND METHODS OF USE THEREOF | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2024-01-04 | — | — | WO | disclosed |
| US-11771697-B2 | Small molecule degraders of polybromo-1 (PBRM1) | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2023-10-03 | — | — | US | disclosed |
| US-11771697-B2 | Small molecule degraders of polybromo-1 (PBRM1) | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2023-10-03 | — | — | US | disclosed |
| US-20230234957-A1 | PROTEIN TAG TO INDUCE LIGAND DEPENDENT DEGRADATION OF PROTEIN/PROTEIN-FUSIONS | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2023-07-27 | — | — | US | disclosed |
| US-20230234957-A1 | PROTEIN TAG TO INDUCE LIGAND DEPENDENT DEGRADATION OF PROTEIN/PROTEIN-FUSIONS | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2023-07-27 | — | — | US | disclosed |
| US-20230226196-A1 | COMPOUNDS FOR TARGETED DEGRADATION OF INTERLEUKIN-2-INDUCIBLE T-CELL KINASE AND METHODS OF USE | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2023-07-20 | — | — | US | disclosed |
| US-20230149551-A1 | ARGININE METHYLTRANSFERASE 5 (PRMT5) DEGRADERS AND USES THEREOF | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2023-05-18 | — | — | US | disclosed |
| US-20230133538-A1 | TARGETED DEGRADERS OF ABERRANT TAU BASED ON THE PET TRACER PBB3 | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2023-05-04 | — | — | US | disclosed |
| US-11542251-B2 | IRAK degraders and uses thereof | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2023-01-03 | — | — | US | disclosed |
| US-20220387604-A1 | SELECTIVE DUAL HISTONE DEACETYLASE 6/8 (HDAC6/8) DEGRADERS AND METHODS OF USE THEREOF | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2022-12-08 | — | — | US | disclosed |
| US-20220047709-A1 | DEGRADERS OF WEE1 KINASE | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2022-02-17 | — | — | US | disclosed |
| US-20210361774-A1 | DEGRADERS OF WILD-TYPE AND MUTANT FORMS OF LRRK2 | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2021-11-25 | — | — | US | disclosed |
| US-20210300941-A1 | BISPECIFIC DEGRADERS | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2021-09-30 | — | — | US | disclosed |
| US-20210230144-A1 | IRAK DEGRADERS AND USES THEREOF | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2021-07-29 | — | — | US | disclosed |
| US-20210038599-A1 | SMALL MOLECULE DEGRADERS OF POLYBROMO-1 (PBRM1) | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2021-02-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (13 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230226196-A1 | COMPOUNDS FOR TARGETED DEGRADATION OF INTERLEUKIN-2-INDUCIBLE T-CELL KINASE AND METHODS OF USE | ITK, IKZF2, PBK | POLB 2759/4885CARM1 1903/4885PRMT6 2778/4885 |
| US-20230133538-A1 | TARGETED DEGRADERS OF ABERRANT TAU BASED ON THE PET TRACER PBB3 | MAPT, PSEN1, PSEN2 | POLB 372/4885CARM1 2212/4885PRMT6 2609/4885 |
| US-12036209-B2 | Compounds and methods for the targeted degradation of Interleukin-1 receptor-associated kinase 4 polypeptides | IRAK1, IRAK4, IRAK2 | POLB 4196/4885CARM1 1030/4885PRMT6 970/4885 |
| US-11771697-B2 | Small molecule degraders of polybromo-1 (PBRM1) | PBRM1, SMARCC1, SMARCC2 | POLB 168/4885CARM1 51/4885PRMT6 1069/4885 |
| US-20210300941-A1 | BISPECIFIC DEGRADERS | CRBN, IDE, PSEN2 | POLB 1723/4885CARM1 1633/4885PRMT6 3391/4885 |
| US-11542251-B2 | IRAK degraders and uses thereof | IRAK2, IRAK1, IRAK4 | POLB 2340/4885CARM1 1404/4885PRMT6 2510/4885 |
| US-20220047709-A1 | DEGRADERS OF WEE1 KINASE | WEE1, WEE2, PPME1 | POLB 1643/4885CARM1 1810/4885PRMT6 2502/4885 |
| US-20210361774-A1 | DEGRADERS OF WILD-TYPE AND MUTANT FORMS OF LRRK2 | LRRK2, CLK2, DDRGK1 | POLB 3013/4885CARM1 2247/4885PRMT6 2318/4885 |
| US-20230234957-A1 | PROTEIN TAG TO INDUCE LIGAND DEPENDENT DEGRADATION OF PROTEIN/PROTEIN-FUSIONS | BET1, STUB1, MDM2 | POLB 3258/4885CARM1 2056/4885PRMT6 2704/4885 |
| US-20230149551-A1 | ARGININE METHYLTRANSFERASE 5 (PRMT5) DEGRADERS AND USES THEREOF | PRMT5, PRMT1, PRMT6 | POLB 1464/4885CARM1 7/4885PRMT6 3/4885 |
| US-20210230144-A1 | IRAK DEGRADERS AND USES THEREOF | IRAK2, IRAK1, IRAK4 | POLB 2340/4885CARM1 1404/4885PRMT6 2510/4885 |
| US-20210038599-A1 | SMALL MOLECULE DEGRADERS OF POLYBROMO-1 (PBRM1) | PBRM1, SMARCC1, SMARCC2 | POLB 168/4885CARM1 51/4885PRMT6 1069/4885 |
| US-20220387604-A1 | SELECTIVE DUAL HISTONE DEACETYLASE 6/8 (HDAC6/8) DEGRADERS AND METHODS OF USE THEREOF | HDAC8, HDAC6, HDAC1 | POLB 919/4885CARM1 117/4885PRMT6 611/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.